Imatinib Aenorasis (Imatinib)

Imatinib binds to the ATP‑binding site of BCR‑ABL, KIT and PDGFRA tyrosine kinases, locking them in an inactive state. This blocks downstream signaling pathways that promote malignant cell proliferation and survival, leading to apoptosis of the cancer cells while sparing most normal tissues.

The dose of Imatinib Aenorasis is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. The exact regimen should be obtained from the treating healthcare professional.

Safety data for Imatinib in pregnancy and lactation are limited. The drug is classified as having an unknown pregnancy category, and potential risks to the fetus or infant cannot be ruled out. Use only if the potential benefit justifies the potential risk, and discuss alternatives with a specialist.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor and remains a standard first‑line option for CML and GIST. Newer agents such as dasatinib or nilotinib may offer faster molecular responses or activity against certain resistant mutations, but they can have different safety profiles and cost considerations. Choice of therapy depends on disease characteristics and patient factors.

Imatinib Aenorasis tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

The medication is supplied as oral tablets that are swallowed whole with a glass of water. It can be taken with or without food, but consistency with regard to meals may help reduce gastrointestinal upset. Patients should follow the dosing schedule prescribed by their clinician.

Serious adverse events include severe neutropenia or other blood cell deficiencies, hepatotoxicity with marked elevation of liver enzymes, and cardiac failure or reduced left‑ventricular function. Patients should be monitored regularly for these complications, and therapy should be adjusted or discontinued if they occur.

Imatinib is contraindicated in individuals with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for patients with severe hepatic impairment, uncontrolled cardiac disease, or those taking medications that strongly interact with its metabolism. The prescribing clinician will assess suitability on a case‑by‑case basis.